Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE3.7300
- TODAY'S CHANGE (%)-0.1300 (-3.3679%)
- Bid / Lots3.6200/ 19
- Ask / Lots3.9100/ 5
- Open / Previous Close3.8200 / 3.8600
- Day Range
- 52 Week Range
- Volume396,962
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 3409 | 3.845 |
| 09:34 ET | 100 | 3.865 |
| 09:38 ET | 1822 | 3.85 |
| 09:39 ET | 1883 | 3.8527 |
| 09:43 ET | 182 | 3.88 |
| 09:45 ET | 300 | 3.865 |
| 09:48 ET | 5312 | 3.85 |
| 09:50 ET | 6816 | 3.83 |
| 09:52 ET | 1386 | 3.825 |
| 09:54 ET | 3716 | 3.815 |
| 09:56 ET | 200 | 3.815 |
| 09:57 ET | 100 | 3.82 |
| 09:59 ET | 2570 | 3.83 |
| 10:01 ET | 1100 | 3.83 |
| 10:03 ET | 29604 | 3.81 |
| 10:06 ET | 899 | 3.79 |
| 10:08 ET | 300 | 3.81 |
| 10:10 ET | 300 | 3.81 |
| 10:12 ET | 100 | 3.79 |
| 10:15 ET | 300 | 3.81 |
| 10:17 ET | 2213 | 3.81 |
| 10:19 ET | 4445 | 3.79 |
| 10:21 ET | 640 | 3.79 |
| 10:24 ET | 800 | 3.79 |
| 10:26 ET | 13021 | 3.79 |
| 10:28 ET | 700 | 3.7929 |
| 10:32 ET | 3755 | 3.774 |
| 10:35 ET | 100 | 3.78 |
| 10:37 ET | 100 | 3.78 |
| 10:39 ET | 100 | 3.78 |
| 10:42 ET | 100 | 3.78 |
| 10:46 ET | 20635 | 3.81 |
| 10:48 ET | 357 | 3.81 |
| 10:50 ET | 400 | 3.81 |
| 10:55 ET | 300 | 3.81 |
| 10:57 ET | 600 | 3.81 |
| 11:02 ET | 305 | 3.81 |
| 11:04 ET | 1247 | 3.8 |
| 11:08 ET | 100 | 3.805 |
| 11:09 ET | 100 | 3.79 |
| 11:11 ET | 2400 | 3.786 |
| 11:13 ET | 1200 | 3.79 |
| 11:20 ET | 600 | 3.7778 |
| 11:22 ET | 300 | 3.7751 |
| 11:27 ET | 101 | 3.78 |
| 11:29 ET | 1040 | 3.77 |
| 11:33 ET | 400 | 3.77 |
| 11:38 ET | 13152 | 3.74 |
| 11:40 ET | 3905 | 3.73 |
| 11:42 ET | 4486 | 3.735 |
| 11:44 ET | 1561 | 3.735 |
| 11:45 ET | 300 | 3.7388 |
| 11:47 ET | 1500 | 3.734 |
| 11:49 ET | 300 | 3.7388 |
| 11:51 ET | 29925 | 3.72 |
| 11:54 ET | 7711 | 3.725 |
| 11:56 ET | 6500 | 3.72 |
| 12:00 ET | 100 | 3.72 |
| 12:02 ET | 1696 | 3.715 |
| 12:09 ET | 5151 | 3.73 |
| 12:12 ET | 304 | 3.725 |
| 12:14 ET | 3277 | 3.736 |
| 12:16 ET | 532 | 3.735 |
| 12:23 ET | 509 | 3.73 |
| 12:25 ET | 750 | 3.728 |
| 12:30 ET | 100 | 3.72 |
| 12:32 ET | 100 | 3.73 |
| 12:39 ET | 235 | 3.725 |
| 12:43 ET | 303 | 3.73 |
| 12:45 ET | 605 | 3.73 |
| 12:48 ET | 5851 | 3.7 |
| 12:50 ET | 1040 | 3.705 |
| 12:52 ET | 100 | 3.705 |
| 12:54 ET | 500 | 3.7053 |
| 12:56 ET | 490 | 3.7083 |
| 12:57 ET | 100 | 3.705 |
| 01:01 ET | 489 | 3.71 |
| 01:06 ET | 100 | 3.71 |
| 01:08 ET | 200 | 3.71 |
| 01:10 ET | 100 | 3.71 |
| 01:14 ET | 898 | 3.71 |
| 01:15 ET | 200 | 3.71 |
| 01:19 ET | 400 | 3.71 |
| 01:21 ET | 100 | 3.705 |
| 01:24 ET | 1703 | 3.7 |
| 01:32 ET | 1100 | 3.71 |
| 01:35 ET | 1466 | 3.715 |
| 01:42 ET | 200 | 3.72 |
| 01:44 ET | 100 | 3.7184 |
| 01:48 ET | 600 | 3.715 |
| 01:50 ET | 100 | 3.72 |
| 01:51 ET | 100 | 3.7244 |
| 01:57 ET | 433 | 3.71 |
| 02:00 ET | 40789 | 3.67 |
| 02:02 ET | 1000 | 3.68 |
| 02:04 ET | 100 | 3.68 |
| 02:09 ET | 650 | 3.68 |
| 02:11 ET | 2434 | 3.68 |
| 02:13 ET | 100 | 3.68 |
| 02:15 ET | 100 | 3.68 |
| 02:18 ET | 1925 | 3.67 |
| 02:20 ET | 200 | 3.67 |
| 02:22 ET | 100 | 3.67 |
| 02:24 ET | 100 | 3.67 |
| 02:26 ET | 100 | 3.68 |
| 02:27 ET | 1650 | 3.67 |
| 02:29 ET | 200 | 3.67 |
| 02:31 ET | 2100 | 3.66 |
| 02:33 ET | 4360 | 3.67 |
| 02:36 ET | 800 | 3.665 |
| 02:38 ET | 2923 | 3.66 |
| 02:40 ET | 1635 | 3.66 |
| 02:42 ET | 400 | 3.66 |
| 02:44 ET | 226 | 3.659 |
| 02:45 ET | 500 | 3.6677 |
| 02:47 ET | 2986 | 3.69 |
| 02:49 ET | 812 | 3.6801 |
| 02:51 ET | 100 | 3.69 |
| 02:56 ET | 1300 | 3.705 |
| 02:58 ET | 3604 | 3.7 |
| 03:00 ET | 1156 | 3.7 |
| 03:03 ET | 262 | 3.7 |
| 03:05 ET | 100 | 3.7 |
| 03:09 ET | 300 | 3.705 |
| 03:12 ET | 1000 | 3.72 |
| 03:18 ET | 1140 | 3.71 |
| 03:21 ET | 541 | 3.71 |
| 03:27 ET | 100 | 3.71 |
| 03:30 ET | 260 | 3.7174 |
| 03:36 ET | 249 | 3.719 |
| 03:39 ET | 459 | 3.715 |
| 03:41 ET | 300 | 3.715 |
| 03:43 ET | 1457 | 3.715 |
| 03:45 ET | 300 | 3.72 |
| 03:50 ET | 212 | 3.725 |
| 03:52 ET | 2470 | 3.73 |
| 03:54 ET | 6185 | 3.72 |
| 03:56 ET | 2929 | 3.715 |
| 03:57 ET | 2821 | 3.73 |
| 03:59 ET | 3797 | 3.73 |
Jun 13, 2024
Investigation Alert: Aldeyra, Eagle Pharmaceuticals, and Blue Ridge Bankshares: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below, from 11:02AM ET on Thursday Jun 13, 2024 by Dow Jones
11:02AM ET on Thursday Jun 13, 2024 by Dow JonesAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease, from 7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 12, 2024
Aldeyra Therapeutics to Host Investor Roundtable Q&A, from 7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
May 29, 2024
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference, from 7:00AM ET on Wednesday May 29, 2024 by Dow Jones
7:00AM ET on Wednesday May 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 221.6M | -7.3x | --- |
Pyxis Oncology Inc | 223.2M | -2.7x | --- |
Acrivon Therapeutics Inc | 223.9M | -2.5x | --- |
Candel Therapeutics Inc | 216.9M | -5.7x | --- |
Prelude Therapeutics Inc | 214.2M | -2.1x | --- |
Q32 Bio Inc | 222.2M | -0.7x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Senior Vice President - Finance, Interim Chief Financial Officer
- Bruce Greenberg
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $221.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -7.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
